MOUNTAIN VIEW, Calif., Jan. 8, 2014 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI ), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 32 nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014, at 3:30 p.m. Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com . A replay of the webcast will be available on the Company's website for two weeks following the presentation.
About ChemoCentryx
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. CCX168, a C5aR inhibitor, has recently completed the first two steps in an ongoing Phase II trial for the treatment of anti-neutrophil cytoplasmic antibody-associated renal vasculitis (AARV). CCX168 appears to be safe, well tolerated and successful in allowing both reduction and elimination of high-dose corticosteroids, part of standard of care for AARV patients, without compromising efficacy or safety during a 12-week treatment period. Vercirnon (also known as Traficet-EN or CCX282) is a specific CCR9 inhibitor for the treatment of inflammatory bowel disease. Other clinical programs include CCX872, a next generation CCR2 inhibitor, and CCX507, a next generation CCR9 inhibitor, both of which are in Phase I clinical testing and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.
Source: ChemoCentryx, Inc.
CCXI-G
Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer Or Markus J. Cappel, Ph.D. Chief Business Officer 650-210-2900 Media: Susan Kinkead Kinkead Communications 415-751-3611 Investors: Caitlyn Murphy Burns McClellan 212-213-0006
